



Attorney's Docket No. 002610-603

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
YEDNOCK et al.) Group Art Unit: 1653
Application No.: 09/127,364) Examiner: D. Lukton
Filed: July 31, 1998) Confirmation No.: 1040
For: ANTI-INFLAMMATORY)
COMPOSITIONS AND METHOD)

RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In complete response to the Office Action of July 9, 2002, Applicants submit the following response. Please amend the application as follows.

In the Specification:

Please delete the paragraph at page 4, lines 8-13 of the originally-filed application and replace with the following:

E1
In preferred embodiments, pharmaceutical compositions and methods of treatment of the invention employ alpha-9 antagonist compounds that inhibit binding between alpha-9 integrin and an alpha-9 integrin ligand. Preferred ligands in this regard include any ligand found to specifically bind to alpha-9 integrin, as exemplified by osteopontin, tenascin, and VCAM-1. Due to its association with inflammatory reactions, VCAM-1 is particular preferred for a test compound in this regard.

Please delete the paragraph beginning at page 22, line 26 of the originally-filed application and replace with the following: